Single Ketamine Dose Eases Severe Depression in 4 Hours

People struggling with severe depression may soon have a faster path to relief than waiting weeks for traditional medications to work.

A comprehensive review of 26 clinical trials involving over 1,100 patients found that a single ketamine infusion significantly reduced depression symptoms in just four hours. Even more remarkable, suicidal thoughts decreased dramatically within 24 hours.

The research, conducted by the University of Connecticut School of Medicine and published in JAMA Psychiatry, focused on patients with treatment-resistant depression. These are people for whom multiple therapies and medications have already failed, leaving them at higher risk of tragic outcomes.

Traditional antidepressants work slowly, gradually elevating serotonin levels over several weeks. Ketamine takes a different approach, blocking glutamate in the brain to create rapid changes in mood and thought patterns.

Patients in the study reported fewer depressive symptoms for up to a week after treatment. Those receiving repeated infusions maintained improvements throughout their treatment period.

The most common side effects like headaches, dizziness, and temporary dissociation resolved within hours. Serious adverse events were rare and mostly unrelated to the ketamine itself.

The Bright Side

For emergency room doctors treating patients in crisis, this research offers a potentially lifesaving tool. When someone arrives with suicidal thoughts, hours matter more than weeks.

Dr. Lama Bazzi, a New York psychiatrist, has seen the difference firsthand with her patients. "The relief they experience is almost immediate, offering them distance from the intensity of their emotions," she told Fox News Digital.

The treatment isn't perfect. Effects from a single infusion are relatively short-lived, so patients with ongoing depression need repeated sessions. Experts also caution that ketamine carries risks of abuse and addiction, requiring careful medical supervision in clinical settings.

Lead researcher Dr. Taeho Greg Rhee emphasizes this treatment is specifically for people who've exhausted other options. "When all existing treatment options fail, patients with severe depression could consider ketamine infusions," he explained.

While not yet FDA-approved specifically for depression, doctors can prescribe ketamine off-label for severe cases. The medication, originally developed as an anesthetic, is now giving people a chance at relief when they need it most.

For the 280 million people worldwide living with major depressive disorder, this research represents more than just another treatment option. It's proof that when traditional approaches fall short, science keeps searching for answers.